CytomX Reports Disappointing FY Results Amid Revenue Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Source: seekingalpha
CytomX Therapeutics' stock reached a 52-week high, gaining 55.98% in pre-market trading.
The company reported a FY GAAP EPS of -$0.15, missing expectations by $0.12, and a revenue decline of 44.8% year-over-year to $76.2 million, primarily due to the completion of performance obligations with Bristol Myers Squibb. This disappointing performance has raised concerns about the company's profitability and future growth potential, leading to a cautious market reaction.
Investors are likely to reassess CytomX's financial health and growth prospects following these results, which may impact future financing and investor relations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTMX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTMX
Wall Street analysts forecast CTMX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.810
Low
6.00
Averages
9.00
High
10.00
Current: 3.810
Low
6.00
Averages
9.00
High
10.00
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GT Biopharma Integrates AI to Accelerate Drug Development
- AI Integration: GT Biopharma has integrated AI tools into the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, with expectations to push multiple new development candidates into pre-IND development by 2027, thereby accelerating clinical timelines and reducing costs.
- Drug Design Optimization: Utilizing AI-guided sequence and structural analyses, GT Biopharma can prioritize candidates with favorable binding, stability, and developability profiles, aiming to eliminate potential failures early in the discovery phase, thus minimizing costly fixes later in development.
- Clinical Trial Progress: Currently, GT Biopharma's lead program GTB-3650 is in a Phase 1 trial for CD33-expressing blood cancers, while its second candidate GTB-5550 began dosing for B7-H3-expressing solid tumors in May 2026, indicating positive momentum in clinical development.
- Future Development Potential: GT Biopharma plans to leverage its AI-enabled discovery engine to replenish its pipeline behind existing projects, targeting multiple new candidates for clinical development by 2027, thereby enhancing its competitive position in the rapidly evolving biopharmaceutical market.
See More
Rigel Pharmaceuticals Appoints New Chief Medical Officer
- Executive Appointment: Rigel Pharmaceuticals has appointed Alison Hannah as Executive Vice President and Chief Medical Officer, succeeding Lisa Rojkjaer, which is expected to drive the company's strategic development in the biotechnology sector.
- Board Changes: Hannah's appointment comes with her resignation from Rigel's Board of Directors, effective July 1, 2026, indicating a significant shift in the company's upper management.
- Extensive Experience: Hannah previously served as Chief Medical Officer at CytomX Therapeutics, overseeing the clinical development of conditionally activated protein therapeutics, showcasing her strong background in the biopharmaceutical field.
- Market Performance: Rigel's stock has traded between $18.24 and $52.24 over the past year, with the current price down 0.73% to $38.84, reflecting a cautious market sentiment regarding the new appointment.
See More
CytomX Expands Collaboration with Regeneron, Validating PROBODY Platform
- Strategic Collaboration Expansion: CytomX Therapeutics has broadened its partnership with Regeneron Pharmaceuticals, securing $37 million upfront and potential milestone payments up to $4 billion, indicating strong market confidence in its PROBODY platform.
- Clinical Development Progress: CytomX's Varseta-m is undergoing dose optimization with 40 patients enrolled, with data expected in the second half of 2026 to support a registrational study start in the first half of 2027, showcasing its potential in tumor treatment.
- Combination Study Plans: Ongoing trials pairing Varseta-m with bevacizumab are anticipated to yield initial data in the first half of 2027, alongside a planned Phase 1/2 study combining multiple drugs in the second half of 2026, further expanding treatment indications.
- Analyst Rating Upgrade: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating on CTMX with a 12-month price target of $11.00, nearly triple the current share price, reflecting optimistic market expectations for CytomX's future growth.
See More
CytomX Expands Collaboration with Regeneron Worth Up to $4B
- Collaboration Expansion: CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to a potential value of up to $4 billion, highlighting the depth of their partnership in cancer therapeutics.
- Funding Injection: CytomX will receive $37 million for nominating two additional targets selected by Regeneron for clinical development, which not only enhances its liquidity but also supports subsequent research efforts.
- Target Selection Opportunity: Regeneron will have the option to select up to six additional targets, a flexibility that could accelerate the development of new therapies, thereby enhancing CytomX's competitive position in the market.
- Potential Revenue: The expanded agreement includes payments linked to target nomination, clinical, and commercial milestones, and CytomX will also be eligible for tiered royalties based on global net sales, further strengthening its long-term profitability.
See More
CytomX (CTMX) Q4 2025 Earnings Transcript
See More
CytomX Therapeutics Q1 2026 Earnings Call Insights
- Significant Clinical Progress: CytomX's Q1 2026 earnings call highlighted excellent clinical progress with Varseta-M in late-line colorectal cancer, aiming for its inclusion in standard care, with a projected registrational study start in the first half of 2027, reflecting the company's strategic ambition in oncology.
- Strong Patient Recruitment: As of now, CytomX has completed enrollment of 40 patients in dose optimization cohorts, with a total of 113 patients enrolled, and expects to provide an overall Phase I data update in the second half of this year, which will be crucial for future FDA interactions.
- Robust Financial Position: CytomX ended Q1 2026 with $346.7 million in cash and equivalents, a significant increase from $137.1 million as of December 31, 2025, demonstrating financial stability post-financing, which supports future R&D initiatives.
- Risk Management Strategies: Management emphasized that diarrhea is the principal adverse event of Varseta-M, and through updated patient management strategies, they expect to substantially reduce the incidence of high-grade diarrhea, indicating proactive risk mitigation efforts.
See More
GT Biopharma Integrates AI to Accelerate Drug Development
- AI Integration: GT Biopharma has integrated AI tools into the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, with expectations to push multiple new development candidates into pre-IND development by 2027, thereby accelerating clinical timelines and reducing costs.
- Drug Design Optimization: Utilizing AI-guided sequence and structural analyses, GT Biopharma can prioritize candidates with favorable binding, stability, and developability profiles, aiming to eliminate potential failures early in the discovery phase, thus minimizing costly fixes later in development.
- Clinical Trial Progress: Currently, GT Biopharma's lead program GTB-3650 is in a Phase 1 trial for CD33-expressing blood cancers, while its second candidate GTB-5550 began dosing for B7-H3-expressing solid tumors in May 2026, indicating positive momentum in clinical development.
- Future Development Potential: GT Biopharma plans to leverage its AI-enabled discovery engine to replenish its pipeline behind existing projects, targeting multiple new candidates for clinical development by 2027, thereby enhancing its competitive position in the rapidly evolving biopharmaceutical market.
See More
Rigel Pharmaceuticals Appoints New Chief Medical Officer
- Executive Appointment: Rigel Pharmaceuticals has appointed Alison Hannah as Executive Vice President and Chief Medical Officer, succeeding Lisa Rojkjaer, which is expected to drive the company's strategic development in the biotechnology sector.
- Board Changes: Hannah's appointment comes with her resignation from Rigel's Board of Directors, effective July 1, 2026, indicating a significant shift in the company's upper management.
- Extensive Experience: Hannah previously served as Chief Medical Officer at CytomX Therapeutics, overseeing the clinical development of conditionally activated protein therapeutics, showcasing her strong background in the biopharmaceutical field.
- Market Performance: Rigel's stock has traded between $18.24 and $52.24 over the past year, with the current price down 0.73% to $38.84, reflecting a cautious market sentiment regarding the new appointment.
See More
CytomX Expands Collaboration with Regeneron, Validating PROBODY Platform
- Strategic Collaboration Expansion: CytomX Therapeutics has broadened its partnership with Regeneron Pharmaceuticals, securing $37 million upfront and potential milestone payments up to $4 billion, indicating strong market confidence in its PROBODY platform.
- Clinical Development Progress: CytomX's Varseta-m is undergoing dose optimization with 40 patients enrolled, with data expected in the second half of 2026 to support a registrational study start in the first half of 2027, showcasing its potential in tumor treatment.
- Combination Study Plans: Ongoing trials pairing Varseta-m with bevacizumab are anticipated to yield initial data in the first half of 2027, alongside a planned Phase 1/2 study combining multiple drugs in the second half of 2026, further expanding treatment indications.
- Analyst Rating Upgrade: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating on CTMX with a 12-month price target of $11.00, nearly triple the current share price, reflecting optimistic market expectations for CytomX's future growth.
See More
CytomX Expands Collaboration with Regeneron Worth Up to $4B
- Collaboration Expansion: CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to a potential value of up to $4 billion, highlighting the depth of their partnership in cancer therapeutics.
- Funding Injection: CytomX will receive $37 million for nominating two additional targets selected by Regeneron for clinical development, which not only enhances its liquidity but also supports subsequent research efforts.
- Target Selection Opportunity: Regeneron will have the option to select up to six additional targets, a flexibility that could accelerate the development of new therapies, thereby enhancing CytomX's competitive position in the market.
- Potential Revenue: The expanded agreement includes payments linked to target nomination, clinical, and commercial milestones, and CytomX will also be eligible for tiered royalties based on global net sales, further strengthening its long-term profitability.
See More
CytomX (CTMX) Q4 2025 Earnings Transcript
See More
CytomX Therapeutics Q1 2026 Earnings Call Insights
- Significant Clinical Progress: CytomX's Q1 2026 earnings call highlighted excellent clinical progress with Varseta-M in late-line colorectal cancer, aiming for its inclusion in standard care, with a projected registrational study start in the first half of 2027, reflecting the company's strategic ambition in oncology.
- Strong Patient Recruitment: As of now, CytomX has completed enrollment of 40 patients in dose optimization cohorts, with a total of 113 patients enrolled, and expects to provide an overall Phase I data update in the second half of this year, which will be crucial for future FDA interactions.
- Robust Financial Position: CytomX ended Q1 2026 with $346.7 million in cash and equivalents, a significant increase from $137.1 million as of December 31, 2025, demonstrating financial stability post-financing, which supports future R&D initiatives.
- Risk Management Strategies: Management emphasized that diarrhea is the principal adverse event of Varseta-M, and through updated patient management strategies, they expect to substantially reduce the incidence of high-grade diarrhea, indicating proactive risk mitigation efforts.
See More
